JOINT FILING AGREEMENT
EXHIBIT
1
This Joint Filing
Agreement dated May 15, 2017 is by and between Camber Capital
Management LLC, a Massachusetts limited liability company, and
Xxxxxxx XxXxxx, an individual (the foregoing are collectively
referred to herein as the "Filers"). Each of the Filers may be
required to file with the United States Securities and Exchange
Commission a statement on Schedule 13G with respect to common
stock, $0.01 par value of Amag Pharmaceuticals, Inc. beneficially
owned by them from time to time. Pursuant to and in accordance with
Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of
1934, as amended, the Filers hereby agree to file a single
statement on Schedule 13D and/or 13G (and any amendments thereto)
on behalf of each of such parties, and hereby further agree to file
this Joint Filing Agreement as an exhibit to such statement, as
required by such rule. This Joint Filing Agreement may be
terminated by any of the Filers upon one week's prior written
notice or such lesser period of notice as the Filers may mutually
agree.
Executed and
delivered as of the date first above written.
By: /s/ Xxxx
Xxxxxx
Xxxx
Xxxxxx
Chief Financial
Officer
XXXXXXX XXXXXX
By: /s/ Xxxxxxx
XxXxxx
